AbbVie (ABBV) Amortizatization of Intangibles (2012 - 2026)
AbbVie (ABBV) reported Amortizatization of Intangibles of $1.7 billion for Q1 2026, down 8.5% year-over-year from $1.9 billion in Q1 2025, and down 4.33% quarter-over-quarter from $1.8 billion in Q4 2025.
AbbVie (ABBV) Amortizatization of Intangibles (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has 15 years of Amortizatization of Intangibles data on file, last reported at $1.7 billion in Q1 2026.
- Amortizatization of Intangibles for Q1 2026 came in at $1.7 billion, down 8.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.3 billion (down 3.39% YoY), and the FY2025 annual result was $7.4 billion, down 2.93% from the prior year.
- Amortizatization of Intangibles retreated to $1.7 billion in Q1 2026 per ABBV's latest filing, from $1.8 billion in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $2.1 billion in Q2 2023 and troughed at $1.7 billion in Q1 2026.
- A 5-year average of $1.9 billion and a median of $1.9 billion in 2024 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2022 and 2023: Amortizatization of Intangibles slipped 10.0% in 2022, then rose 16.67% in 2023.
- A 5-year view of Amortizatization of Intangibles shows it stood at $2.0 billion in 2022, then decreased by 7.85% to $1.8 billion in 2023, then increased by 1.68% to $1.9 billion in 2024, then dropped by 5.18% to $1.8 billion in 2025, then dropped by 4.33% to $1.7 billion in 2026.
- Business Quant data shows ABBV's Amortizatization of Intangibles at $1.7 billion in Q1 2026, $1.8 billion in Q4 2025, and $1.9 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | - |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 1.70 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 931.00 Mn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 596.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.70 Bn |
| Mar 31, 2026 | 1.70 Bn |
| Dec 31, 2025 | 1.78 Bn |
| Dec 31, 2025 | 1.78 Bn |
| Sep 30, 2025 | 1.90 Bn |
| Sep 30, 2025 | 1.90 Bn |
| Jun 30, 2025 | 1.90 Bn |
| Jun 30, 2025 | 1.90 Bn |
| Mar 31, 2025 | 1.86 Bn |
| Mar 31, 2025 | 1.86 Bn |
| Dec 31, 2024 | 1.87 Bn |
| Dec 31, 2024 | 1.87 Bn |
| Sep 30, 2024 | 1.90 Bn |
| Sep 30, 2024 | 1.90 Bn |
| Jun 30, 2024 | 1.90 Bn |
| Jun 30, 2024 | 1.90 Bn |
| Mar 31, 2024 | 1.90 Bn |
| Mar 31, 2024 | 1.90 Bn |
| Dec 31, 2023 | 1.84 Bn |
| Dec 31, 2023 | 1.84 Bn |